Pulmonary Hypertension Related to Congenital Heart Disease: A Call to Action Evaluation (ID: i795a) Survey

Question Title

* 2. How many patients with CHD do you manage?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

Private practice

Managed Care

Research

Pharmaceutical industry

Other (please specify)

Question Title

* 4. After participating in this activity how confident are you in managing a patient diagnosed with pulmonary arterial hypertension related to congenital heart disease (CHD-PAH)?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Increased knowledge of the pathophysiology and clinical subtypes of CHD-PAH

Be better prepared to evaluate patients with CHD and suspected/known PAH and refer to specialist PH centers

Greater understanding of the process patients must undergo to confirm a PAH diagnosis

Expand knowledge of current evidence-based recommendations for the management of CHD-PAH

Improved understanding of safety and efficacy data supporting the role of PAH treatments in patients with CHD-PAH

Better awareness of the importance of shared decision-making in the management of CHD-PAH

Question Title

* 8. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Constant changing guidelines

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Other (please specify)

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
List the clinical subtypes of CHD	List the clinical subtypes of CHD Strongly agree	List the clinical subtypes of CHD Agree	List the clinical subtypes of CHD Neutral	List the clinical subtypes of CHD Disagree	List the clinical subtypes of CHD Strongly disagree
Describe the pathophysiology of PAH development in patients with CHD-PAH	Describe the pathophysiology of PAH development in patients with CHD-PAH Strongly agree	Describe the pathophysiology of PAH development in patients with CHD-PAH Agree	Describe the pathophysiology of PAH development in patients with CHD-PAH Neutral	Describe the pathophysiology of PAH development in patients with CHD-PAH Disagree	Describe the pathophysiology of PAH development in patients with CHD-PAH Strongly disagree
Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH	Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH Strongly agree	Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH Agree	Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH Neutral	Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH Disagree	Apply risk factors and determinants of prognosis to the evaluation of patients with CHD and suspected/known PAH Strongly disagree
Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies	Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies Strongly agree	Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies Agree	Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies Neutral	Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies Disagree	Implement guideline recommendations and efficacy and safety data of PAH pharmacotherapies Strongly disagree
Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life	Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life Strongly agree	Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life Agree	Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life Neutral	Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life Disagree	Utilize shared decision-making and multidisciplinary approaches to mitigate adverse events and improve patient satisfaction and quality of life Strongly disagree

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Richard Krasuski,  MD, FACC, FAHA, FESC, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Ioana R. Preston, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 12. The content presented: 

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state: 

Pulmonary Hypertension Related to Congenital Heart Disease: A Call to Action Evaluation (ID: i795a)

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with CHD do you manage?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity how confident are you in managing a patient diagnosed with pulmonary arterial hypertension related to congenital heart disease (CHD-PAH)?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice?

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Richard Krasuski,  MD, FACC, FAHA, FESC, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

Ioana R. Preston, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with CHD do you manage?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity how confident are you in managing a patient diagnosed with pulmonary arterial hypertension related to congenital heart disease (CHD-PAH)?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice?

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating. After participating in today’s activity, I am now able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating. Richard Krasuski, MD, FACC, FAHA, FESC, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. Ioana R. Preston, MD, effectively:

Question Title

* 12. The content presented:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 15. If you indicated that you perceived commercial bias or influence, please describe:

* 9. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now able to:

* 10. Please rate your level of agreement by checking the appropriate rating.

Richard Krasuski,  MD, FACC, FAHA, FESC, effectively:

* 11. Please rate your level of agreement by checking the appropriate rating.

Ioana R. Preston, MD, effectively:

* 12. The content presented: 

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state: 